Compare GenXone SA with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a -162.26% CAGR growth in Operating Profits over the last 5 years
2
Poor long term growth as Net Sales has grown by an annual rate of -56.23% and Operating profit at -162.26% over the last 5 years
3
Flat results in Jun 26
4
Risky -
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
PLN 19 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.39
-24.44%
2.38
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2026)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.75%
0%
-1.75%
6 Months
-11.67%
0%
-11.67%
1 Year
-5.72%
0%
-5.72%
2 Years
-41.67%
0%
-41.67%
3 Years
-64.33%
0%
-64.33%
4 Years
-80.0%
0%
-80.0%
5 Years
0%
0%
0.0%
GenXone SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-56.23%
EBIT Growth (5y)
-162.26%
EBIT to Interest (avg)
-0.67
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.47
Sales to Capital Employed (avg)
0.19
Tax Ratio
0.16%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
33.91%
ROE (avg)
9.23%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.51
EV to EBIT
-7.81
EV to EBITDA
-13.73
EV to Capital Employed
3.47
EV to Sales
6.97
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-44.44%
ROE (Latest)
-24.44%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
0.60
0.50
20.00%
Operating Profit (PBDIT) excl Other Income
-0.40
-0.40
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.30
-0.50
40.00%
Operating Profit Margin (Excl OI)
-1,019.30%
-1,086.70%
6.74%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 20.00% vs -44.44% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 40.00% vs -150.00% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2.30
1.80
27.78%
Operating Profit (PBDIT) excl Other Income
-1.80
-2.90
37.93%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.60
-3.90
33.33%
Operating Profit Margin (Excl OI)
-1,240.20%
-2,381.40%
114.12%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 27.78% vs -25.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 33.33% vs -5.41% in Dec 2024
About GenXone SA 
GenXone SA
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






